(Q35581174)

9 August 2017

1 reference

title

Emerging treatments for ovarian cancer (English)

1 reference

9 August 2017

1 reference

1

1 reference

9 August 2017

M Janice Lu

2

1 reference

PubMed ID

14610922

9 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Expert Opinion on Emerging Drugs

9 August 2017

1 reference

9 August 2017

8

1 reference

9 August 2017

203-216

1 reference

9 August 2017

1

1 reference

The epidemiology of ovarian cancer

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Second-look laparotomy for stage III epithelial ovarian cancer: rationale and current issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Activity of anthracyclines in refractory ovarian cancer: recent experience and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Adenovirus-based p53 gene therapy in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.203

21 January 2018

Identifiers

DOI

10.1517/14728214.8.1.203

1 reference

9 August 2017

1 reference

PubMed ID

14610922